Given the evidence that reduced EAAT2 is associated with brain diseases, it could be hypothesized that MS protects against EAAT2 dysregulation, which may play a role in normal cognition [52,53], although this hypothesis is only speculative and additional studies are needed to better understand the mechanisms by which EAAT2 expression or activity could alter cognitive functions. The gene discussed is SLC1A2; the disease is myeloid sarcoma.